FDA To Probe Prostate Cancer Drug Class

Law360, New York (May 4, 2010, 3:54 PM EDT) -- A class of prostate cancer drugs marketed by Pfizer Inc., Sanofi-Aventis SA and Bayer AG may be linked to an increased risk of health issues, including sudden death, and will be investigated, the U.S. Food and Drug Administration has said.

The drugs, gonadotropin-releasing hormone agonists, have been linked with a “small increased risk” of diabetes, heart attack, stroke and sudden death, the FDA said in a statement issued Monday.

The agency, which released the findings after preliminary research, is continuing its investigation, it said.

The drugs...
To view the full article, register now.